Charles Schwab Investment Management Inc Nektar Therapeutics Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Nektar Therapeutics stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,128,319 shares of NKTR stock, worth $1.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,128,319

Previous 1,093,926 3.14%

Holding current value

$1.4 Million

Previous $612,000 71.41%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$0.49 - $0.96 $16,852 - $33,017	34,393 Added 3.14%	1,128,319 $1.05 Million
Q4 2023 Feb 06, 2024	BUY	$0.42 - $0.57 $8,348 - $11,329	19,877 Added 1.85%	1,093,926 $612,000
Q3 2023 Nov 08, 2023	BUY	$0.51 - $1.05 $37,748 - $77,717	74,017 Added 7.4%	1,074,049 $644,000
Q2 2023 Aug 09, 2023	SELL	$0.53 - $1.03 $107,821 - $209,540	-203,437 Reduced 16.9%	1,000,032 $580,000
Q1 2023 May 11, 2023	SELL	$0.64 - $3.15 $110,542 - $544,077	-172,723 Reduced 12.55%	1,203,469 $842,000

Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $34,333 - $72,387	16,913 Added 1.24%	1,376,192 $3.11 Million
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $150,850 - $255,057	49,622 Added 3.79%	1,359,279 $4.35 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $1.15 Million - $2.23 Million	361,720 Added 38.16%	1,309,657 $4.98 Million
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $71,011 - $234,200	17,070 Added 1.83%	947,937 $5.11 Million
Q4 2021 Feb 11, 2022	BUY	$10.83 - $18.41 $252,274 - $428,842	23,294 Added 2.57%	930,867 $12.6 Million
Q3 2021 Nov 16, 2021	BUY	$13.07 - $18.84 $213,145 - $307,242	16,308 Added 1.83%	907,573 $16.3 Million
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $327,922 - $404,940	19,850 Added 2.28%	891,265 $15.3 Million
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $2.15 Million - $3.31 Million	-129,946 Reduced 12.98%	871,415 $17.4 Million
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $779,495 - $940,633	49,429 Added 5.19%	1,001,361 $17 Million
Q3 2020 Nov 13, 2020	BUY	$16.59 - $24.79 $387,127 - $578,474	23,335 Added 2.51%	951,932 $15.8 Million
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $1.55 Million - $2.15 Million	91,885 Added 10.98%	928,597 $21.5 Million
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $772,046 - $1.49 Million	53,355 Added 6.81%	836,712 $14.9 Million
Q4 2019 Feb 07, 2020	SELL	$15.87 - $23.12 $4.23 Million - $6.16 Million	-266,568 Reduced 25.39%	783,357 $16.9 Million
Q3 2019 Nov 08, 2019	BUY	$16.91 - $36.27 $5.06 Million - $10.9 Million	299,269 Added 39.87%	1,049,925 $19.1 Million
Q2 2019 Aug 09, 2019	BUY	$31.0 - $36.3 $852,810 - $998,612	27,510 Added 3.8%	750,656 $26.7 Million
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $660,053 - $968,761	20,901 Added 2.98%	723,146 $24.3 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $787,741 - $1.47 Million	25,887 Added 3.83%	702,245 $23.1 Million
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $9.77 Million - $14.4 Million	-210,336 Reduced 23.72%	676,358 $41.2 Million
Q2 2018 Aug 08, 2018	SELL	$46.25 - $104.45 $12.6 Million - $28.4 Million	-271,546 Reduced 23.44%	886,694 $43.3 Million
Q1 2018 May 07, 2018	BUY	$57.4 - $108.44 $20.4 Million - $38.6 Million	355,766 Added 44.33%	1,158,240 $123 Million
Q4 2017 Jan 17, 2018	BUY	$23.02 - $60.5 $2.28 Million - $6 Million	99,192 Added 14.1%	802,474 $47.9 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $12.5 Million - $16.9 Million	703,282	703,282 $16.9 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Nektar Therapeutics Transaction History